Prednisone Explained

Verifiedrevid:464213538
Verifiedfields:changed
Tradename:Deltasone, Liquid Pred, Orasone, others
Dailymedid:Prednisone
Pregnancy Au:A
Routes Of Administration:By mouth
Atc Prefix:A07
Atc Suffix:EA03
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Us:Rx-only
Bioavailability:70%
Metabolism:prednisolone (liver)
Elimination Half-Life:3 to 4 hours in adults. 1 to 2 hours in children[2]
Excretion:Kidney
Cas Number:53-03-2
Pubchem:5865
Iuphar Ligand:7096
Drugbank:DB00635
Chemspiderid:5656
Unii:VB0R961HZT
Kegg:C07370
Chebi:8382
Chembl:635
Iupac Name:17,21-dihydroxypregna-1,4-diene-3,11,20-trione
C:21
H:26
O:5
Smiles:O=C(CO)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4C(=O)C[C@@]23C
Stdinchi:1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
Stdinchikey:XOFYZVNMUHMLCC-ZPOLXVRWSA-N

Prednisone is a glucocorticoid medication mostly used to suppress the immune system and decrease inflammation in conditions such as asthma, COPD, and rheumatologic diseases.[3] It is also used to treat high blood calcium due to cancer and adrenal insufficiency along with other steroids.[3] It is taken by mouth.[3]

Common side effects may include cataracts, bone loss, easy bruising, muscle weakness, and thrush.[3] Other side effects include weight gain, swelling, high blood sugar, increased risk of infection, and psychosis.[4] [3] It is generally considered safe in pregnancy and low doses appear to be safe while the user is breastfeeding.[5] After prolonged use, prednisone must be stopped gradually.[3]

Prednisone is a prodrug and must be converted to prednisolone by the liver before it becomes active.[6] [7] Prednisolone then binds to glucocorticoid receptors, activating them and triggering changes in gene expression.[4]

Prednisone was patented in 1954 and approved for medical use in the United States in 1955.[3] [8] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[3] In 2021, it was the 28th most commonly prescribed medication in the United States, with more than 19million prescriptions.[10] [11]

Medical uses

Prednisone is used for many different autoimmune diseases and inflammatory conditions, including asthma, gout, COPD, CIDP, rheumatic disorders, allergic disorders, ulcerative colitis and Crohn's disease, granulomatosis with polyangiitis, adrenocortical insufficiency, hypercalcemia due to cancer, thyroiditis, laryngitis, severe tuberculosis, hives, eczema, lipid pneumonitis, pericarditis, multiple sclerosis, nephrotic syndrome, sarcoidosis, to relieve the effects of shingles, lupus, myasthenia gravis, poison oak exposure, Ménière's disease, autoimmune hepatitis, giant cell arteritis, the Herxheimer reaction that is common during the treatment of syphilis, Duchenne muscular dystrophy, uveitis, and as part of a drug regimen to prevent rejection after organ transplant.[12] [13]

Prednisone has also been used in the treatment of migraine headaches and cluster headaches and for severe aphthous ulcer.[14] Prednisone is used as an antitumor drug.[15]

Prednisone is often also prescribed as a form of treatment for sudden sensorineural hearing loss (SSNHL).[16]

Prednisone can be used in the treatment of decompensated heart failure to increase renal responsiveness to diuretics, especially in heart failure patients with refractory diuretic resistance with large doses of loop diuretics.[17] [18] [19] [20] [21] [22] In terms of the mechanism of action for this purpose: prednisone, a glucocorticoid, can improve renal responsiveness to atrial natriuretic peptide by increasing the density of natriuretic peptide receptor type A in the renal inner medullary collecting duct, thereby inducing a potent diuresis.[23]

At high doses it may be used to prevent rejection following organ transplant.[3]

Side effects

Short-term side effects, as with all glucocorticoids, include high blood glucose levels (especially in patients with diabetes mellitus or on other medications that increase blood glucose, such as tacrolimus) and mineralocorticoid effects such as fluid retention.[24] The mineralocorticoid effects of prednisone are minor, which is why it is not used in the management of adrenal insufficiency, unless a more potent mineralocorticoid is administered concomitantly.

It can also cause depression or depressive symptoms and anxiety in some individuals.[25] [26]

Long-term side effects include Cushing's syndrome, steroid dementia syndrome,[27] truncal weight gain, glaucoma and cataracts, diabetes mellitus type 2, and depression upon dose reduction or cessation.[28] Long-term steroids can also increase the risk of osteoporosis, but research has found that few of these people were taking medications to protect bones.[29] [30] Prednisone also results in leukocytosis.[31]

Major

Source:

Minor

Source:

Dependency

Adrenal suppression will begin to occur if prednisone is taken for longer than seven days. Eventually, this may cause the body to temporarily lose the ability to manufacture natural corticosteroids (especially cortisol), which results in dependence on prednisone. For this reason, prednisone should not be abruptly stopped if taken for more than seven days; instead, the dosage should be gradually reduced. This weaning process may be over a few days if the course of prednisone was short but may take weeks or months[33] if the patient had been on long-term treatment. Abrupt withdrawal may lead to an Addisonian crisis. For those on chronic therapy, alternate-day dosing may preserve adrenal function and thereby reduce side effects.[34]

Glucocorticoids act to inhibit feedback of both the hypothalamus, decreasing corticotropin-releasing hormone (CRH), and corticotrophs in the anterior pituitary gland, decreasing the amount of adrenocorticotropic hormone (ACTH). For this reason, glucocorticoid analogue drugs such as prednisone down-regulate the natural synthesis of glucocorticoids. This mechanism leads to dependence in a short time and can be dangerous if medications are withdrawn too quickly. The body must have time to begin synthesis of CRH and ACTH and for the adrenal glands to begin functioning normally again.

Prednisone may start to result in the suppression of the hypothalamic–pituitary–adrenal (HPA) axis if used at doses 7–10 mg or higher for several weeks. This is approximately equal to the amount of endogenous cortisol produced by the body every day. As such, the HPA axis starts to become suppressed and atrophy. If this occurs the patient should be tapered off prednisone slowly to give the adrenal gland enough time to regain its function and endogenous production of steroids.

Withdrawal

The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case-by-case basis, taking into consideration the underlying condition being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:

Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who have received treatment for three weeks or less and who are not included in the patient groups described above.

During corticosteroid withdrawal, the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.[35]

Pharmacology

Prednisone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties.[36] [37] Prednisone is a prodrug; it is metabolised in the liver by 11-β-HSD to prednisolone, the active drug. Prednisone has no substantial biological effects until converted via hepatic metabolism to prednisolone.[38]

Pharmacokinetics

Prednisone is absorbed in the gastrointestinal tract and has a half-life of 2–3 hours.[37] it has a volume of distribution of 0.4–1 L/kg.[39] The drug is cleared by hepatic metabolism using cytochrome P450 enzymes. Metabolites are excreted in the bile and urine.[39]

Lodotra

"Lodotra" is the brand name of an oral formulation, which releases prednisone four hours after ingestion. It is indicated for rheumatoid arthritis with morning stiffness. Taken at 10 p.m., it releases the drug at around 2 a.m. The plasmic peak level is reached at 4 a.m., which is considered to be the optimal time for relieving morning stiffness. The drug was approved in the European Union, in January 2009.[40] [41]

Industry

The pharmaceutical industry uses prednisone tablets for the calibration of dissolution testing equipment according to the United States Pharmacopeia (USP).

Chemistry

Prednisone is a synthetic pregnane corticosteroid and derivative of cortisone and is also known as δ1-cortisone or 1,2-dehydrocortisone or as 17α,21-dihydroxypregna-1,4-diene-3,11,20-trione.[42] [43]

History

The first isolation and structure identifications of prednisone and prednisolone were done in 1950 by Arthur Nobile.[44] [45] [46] The first commercially feasible synthesis of prednisone was carried out in 1955 in the laboratories of Schering Corporation, which later became Schering-Plough Corporation, by Arthur Nobile and coworkers.[47] They discovered that cortisone could be microbiologically oxidized to prednisone by the bacterium Corynebacterium simplex. The same process was used to prepare prednisolone from hydrocortisone.[48]

The enhanced adrenocorticoid activity of these compounds over cortisone and hydrocortisone was demonstrated in mice.

Prednisone and prednisolone were introduced in 1955 by Schering and Upjohn, under the brand names Meticorten[49] and Delta-Cortef,[50] respectively.

Notes and References

  1. Web site: Product monograph brand safety updates . . 7 July 2016 . 3 April 2024.
  2. Pickup ME . Clinical pharmacokinetics of prednisone and prednisolone . Clinical Pharmacokinetics . 4 . 2 . 111–128 . 1979 . 378499 . 10.2165/00003088-197904020-00004 . 12218704 .
  3. Web site: Prednisone Monograph for Professionals . Drugs.com . AHFS . 24 December 2018 .
  4. Book: Brunton L . Goodman & Gilman's the pharmacological basis of therapeutics . 2017 . McGraw-Hill Education . 978-1-25-958473-2 . 739, 746, 1237. 13.
  5. Web site: Prednisone Use During Pregnancy . Drugs.com . 24 December 2018 .
  6. Web site: Product Information Panafcort (prednisone) Panafcortelone (prednisolone) . TGA eBusiness Services . Aspen Pharmacare Australia Pty Ltd . 30 June 2018 . St Leonards, Australia . 1–2 . PDF . 11 July 2017.
  7. Buttgereit F, Gibofsky A . Delayed-release prednisone - a new approach to an old therapy . Expert Opinion on Pharmacotherapy . 14 . 8 . 1097–1106 . June 2013 . 23594208 . 10.1517/14656566.2013.782001 . 22720230 .
  8. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 485 .
  9. Book: ((World Health Organization)) . The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . 2023 . 10665/371090 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2023.02 . free .
  10. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  11. Web site: Prednisone - Drug Usage Statistics . ClinCalc . 14 January 2024.
  12. Book: Corticosteroids . 30 May 2014 . 31643719 . https://www.ncbi.nlm.nih.gov/books/NBK548400/ . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury . 19 March 2020 . NBK548400 .
  13. Web site: Prednisone. The American Society of Health-System Pharmacists. 3 April 2011.
  14. Book: Wackym PA, Snow JB . Ballenger's Otorhinolaryngology: Head and Neck Surgery . 2017 . PMPH USA . 9781607951773 . 1185 .
  15. Web site: U.S. National Library of Medicine . Medical Subject Headings. . Antineoplastic Agents, Hormonal . 2009 . 11 November 2010 .
  16. Web site: 22 May 2015 . Steroid Treatments Equally Effective Against Sudden Deafness . 9 May 2022 . National Institutes of Health (NIH) . EN.
  17. Riemer AD . Application of the newer corticosteroids to augment diuresis in congestive heart failure . The American Journal of Cardiology . 1 . 4 . 488–496 . April 1958 . 13520608 . 10.1016/0002-9149(58)90120-6 .
  18. Newman DA . Reversal of intractable cardiac edema with prednisone . New York State Journal of Medicine . 59 . 4 . 625–633 . February 1959 . 13632954 .
  19. Zhang H, Liu C, Ji Z, Liu G, Zhao Q, Ao YG, Wang L, Deng B, Zhen Y, Tian L, Ji L, Liu K . Prednisone adding to usual care treatment for refractory decompensated congestive heart failure . International Heart Journal . 49 . 5 . 587–595 . September 2008 . 18971570 . 10.1536/ihj.49.587 . free .
  20. Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K . Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance . The Canadian Journal of Cardiology . 23 . 11 . 865–868 . September 2007 . 17876376 . 2651362 . 10.1016/s0828-282x(07)70840-1 .
  21. Liu C, Chen H, Zhou C, Ji Z, Liu G, Gao Y, Tian L, Yao L, Zheng Y, Zhao Q, Liu K . Potent potentiating diuretic effects of prednisone in congestive heart failure . Journal of Cardiovascular Pharmacology . 48 . 4 . 173–176 . October 2006 . 17086096 . 10.1097/01.fjc.0000245242.57088.5b . 45800521 . free .
  22. Massari F, Mastropasqua F, Iacoviello M, Nuzzolese V, Torres D, Parrinello G . The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde? . The American Journal of Emergency Medicine . 30 . 3 . 517.e5–517.10 . March 2012 . 21406321 . 10.1016/j.ajem.2011.01.023 .
  23. Liu C, Chen Y, Kang Y, Ni Z, Xiu H, Guan J, Liu K . Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure . The Journal of Pharmacology and Experimental Therapeutics . 339 . 1 . 203–209 . October 2011 . 21737535 . 10.1124/jpet.111.184796 . 1892149 .
  24. News: Prednisone and other corticosteroids: Balance the risks and benefits . Mayo Clinic. 7 April 2017.
  25. Web site: Prednisone Information . Drugs.com .
  26. Web site: Prednisone . MedlinePlus Drug Information .
  27. Wolkowitz OM, Lupien SJ, Bigler ED . The "steroid dementia syndrome": a possible model of human glucocorticoid neurotoxicity . Neurocase . 13 . 3 . 189–200 . June 2007 . 17786779 . 10.1080/13554790701475468 . 39340010 .
  28. News: Steroids . April 2016 . Australian Department of Health & Human Services . 14 June 2018 .
  29. 21 June 2022 . Polymyalgia rheumatica: treatment reviews are needed . 5 August 2022 . NIHR Evidence . 10.3310/nihrevidence_51304 . 251774691 . en-GB.
  30. Sokhal BS, Hider SL, Paskins Z, Mallen CD, Muller S . Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study . Rheumatology Advances in Practice . 5 . 3 . rkab094 . 2021 . 34988356 . 8712242 . 10.1093/rap/rkab094 .
  31. Book: Miller NR, Walsh FB, Hoyt WF . Walsh and Hoyt's Clinical Neuro-ophthalmology . 2005 . Lippincott Williams & Wilkins . 9780781748117 . 1062 .
  32. Schakman O, Gilson H, Kalista S, Thissen JP . Mechanisms of muscle atrophy induced by glucocorticoids . Hormone Research . 72 . Suppl 1 . 36–41 . November 2009 . 19940494 . 10.1159/000229762 . 1 July 2024 . 21997662 .
  33. News: Steroid Drug Withdrawal Symptoms, Treatment & Prognosis . MedicineNet . 14 June 2018 .
  34. Web site: Therapeutic and Adverse Effects of Glucocorticoids . Bello CS, Garrett SD . U.S. Pharmacist Continuing Education Program . https://web.archive.org/web/20080711145809/http://www.uspharmacist.com/NewLook/CE/glucocort/lesson.htm . 11 July 2008.
  35. Iliopoulou A, Abbas A, Murray R . 19 May 2013 . How to manage withdrawal of glucocorticoid therapy . Prescriber . 24 . 10 . 23–29 . 10.1002/psb.1060. 72082017 .
  36. Becker DE . Basic and clinical pharmacology of glucocorticosteroids . Anesthesia Progress . 60 . 1 . 25–31; quiz 32 . Spring 2013 . 23506281 . 3601727 . 10.2344/0003-3006-60.1.25 .
  37. Web site: Prednisone . DrugBank . 29 January 2019.
  38. Web site: Prednisone . MedlinePlus . NIH U.S. National Library of Medicine.
  39. Schijvens AM, Ter Heine R, de Wildt SN, Schreuder MF . Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome . Pediatric Nephrology . 34 . 3 . 389–403 . March 2019 . 29549463 . 6349812 . 10.1007/s00467-018-3929-z . free .
  40. Web site: Delayed-release prednisone (Lodotra™) approved in EU for treatment of rheumatoid arthritis. Wan Y. 8 January 2009. 22 November 2009. 9 July 2009. https://web.archive.org/web/20090709195015/http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---January/08/Delayed-release-prednisone-Lodotra-approved-in-EU-for-treatment-of-rheumatoid-arthritis/. dead.
  41. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R . Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial . Lancet . 371 . 9608 . 205–214 . January 2008 . 18207016 . 10.1016/S0140-6736(08)60132-4 . 6197980 .
  42. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 1013–.
  43. Book: Index Nominum 2000: International Drug Directory. January 2000. Taylor & Francis. 978-3-88763-075-1. 871–.
  44. Wainwright M . The secret of success: Arthur Nobile's discovery of the steroids prednisone and prednisolone in the 1950s revolutionised the treatment of arthritis . Chemistry in Britain . 34 . 1 . 1998 . 46 . 106716069 .
  45. Web site: Inventor Profile: Arthur Nobile . National Inventors Hall of Fame. dead . https://web.archive.org/web/20120612062323/http://www.invent.org/hall_of_fame/355.html . 12 June 2012.
  46. Web site: Arthur Nobile . New Jersey Inventors Hall of Fame . dead . https://web.archive.org/web/20110901232600/http://www.stevens.edu/njinvent/2000/inductees_2000/nobile.html . 1 September 2011.
  47. Book: Merck Index . 14th . 1327 . 2006 . Merck & Co. Inc . 978-0-911910-00-1 .
  48. Herzog HL, Nobile A, Tolksdorf S, Charney W, Hershberg EB, Perlman PL . New antiarthritic steroids . Science . 121 . 3136 . 176 . February 1955 . 13225767 . 10.1126/science.121.3136.176 . 1955Sci...121..176H .
  49. Web site: Meticorten: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) .
  50. Web site: Delta-Cortef: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) .